HRT and Bone Density: What Your DEXA Is Telling You and What HRT Can Do About It

Bone density is one of the clearest examples of why hormone therapy is more than a quality-of-life intervention. The accelerated bone loss that follows menopause is a direct, measurable consequence of estrogen withdrawal, and it is one of the few areas where HRT has both prevention and treatment evidence at the population level. Yet most women only learn about their bone density in their 60s, when the first DEXA scan reveals osteopenia or osteoporosis, and the question becomes what to do about it. This guide explains what your DEXA scan actually tells you, what HRT does for bone density, when HRT is the right choice, and when other medications are more appropriate.

HRT and Bone Density: Why Estrogen Matters for Bone

Bone is a constantly remodeling tissue. Specialized cells called osteoclasts break down old bone, and osteoblasts build new bone in its place. Estrogen acts as a brake on the resorption side of this equation. It restrains osteoclast activity and supports osteoblast function, keeping the balance favorable for bone maintenance. When estrogen drops at menopause, that brake comes off. Resorption accelerates while formation does not keep pace, and bone density falls. The most rapid bone loss occurs in the first 5 to 7 years after menopause, with women losing approximately 10 to 20 percent of their lumbar spine bone density during this period if untreated.

This is not a slow process. It is one of the fastest physiological changes that happens at menopause, and it is one of the reasons fracture risk rises substantially in postmenopausal women compared to age-matched men. By age 65, approximately one in three women has osteoporosis. The fractures that follow, particularly hip fractures, carry significant morbidity and mortality consequences that the original injury suggests but the public health conversation often understates.

Understanding Your DEXA Results

A DEXA (dual-energy X-ray absorptiometry) scan measures bone mineral density at standard sites, usually the lumbar spine and the hip. The result is reported as a T-score and a Z-score. The T-score compares your bone density to a healthy 30-year-old woman, the reference for peak bone mass. The Z-score compares your bone density to other women of the same age. The T-score is the value used clinically to diagnose osteopenia and osteoporosis.

The T-score thresholds are: above -1.0 is normal, between -1.0 and -2.5 is osteopenia (low bone mass), and below -2.5 is osteoporosis. A T-score of -2.5 means your bone density is 2.5 standard deviations below peak. Each one-standard-deviation drop roughly doubles fracture risk, so a woman with a T-score of -2.5 has roughly four times the fracture risk of a woman at -0.5, even though both are categorized differently. This is why the difference between osteopenia and osteoporosis is not a hard biological boundary but a clinically useful threshold for treatment decisions.

What the Evidence Shows on HRT and Bone

HRT is one of the most extensively studied interventions for postmenopausal bone loss. The WHI bone substudy by Cauley and colleagues, published in JAMA, demonstrated that women on combined HRT had significantly fewer fractures, including a 33 percent reduction in hip fractures, compared to placebo. This benefit was seen even in the WHI population, which was not selected for osteoporosis risk. Subsequent studies in higher-risk populations have shown larger absolute benefits.

The bone density gains on HRT are most pronounced in the first 1 to 3 years of therapy, with continued maintenance afterward. When HRT is stopped, bone loss resumes at approximately the same rate as untreated postmenopausal women, which is why the decision about how long to continue HRT for bone protection is part of the long-term treatment conversation. The 2022 NAMS position statement on hormone therapy explicitly supports HRT as a first-line option for fracture prevention in symptomatic perimenopausal and postmenopausal women.

Current evidence supports initiating HRT within 10 years of the menopausal transition, or before age 60, for the most favorable benefit-to-risk profile. For bone density specifically, the timing principle matters because the period of fastest bone loss is also the period when HRT is most likely to be initiated for symptomatic reasons, allowing the bone benefit to be captured alongside the symptom relief. The WHI studied oral conjugated equine estrogen plus medroxyprogesterone acetate, not the modern formulation of transdermal estradiol plus micronized progesterone used today, but the bone-protective effects of estrogen are class-wide and persist with the modern formulation.

HRT Compared to Bisphosphonates

Bisphosphonates (alendronate, risedronate, zoledronic acid) are the standard pharmacologic option for women with osteoporosis who are not candidates for or do not want HRT. They work by inhibiting osteoclast activity directly, reducing bone resorption. They are effective at increasing bone density and reducing fracture risk, with the strongest evidence for vertebral and hip fractures.

The choice between HRT and bisphosphonates depends on multiple factors. For a 50- to 60-year-old woman with vasomotor symptoms and osteopenia or early osteoporosis, HRT addresses both problems with a single intervention and is often the preferred choice. For a 70-year-old woman with established osteoporosis, no vasomotor symptoms, and significant time since menopause, bisphosphonates are typically more appropriate. For women with very high fracture risk, severe osteoporosis, or established vertebral fractures, anabolic agents like teriparatide or romosozumab may be considered. The right choice is individualized and depends on the woman’s overall clinical picture, not on bone density alone.

Who Needs a DEXA and When

Most current guidance recommends a baseline DEXA scan at the time of menopause or at age 65, whichever comes first. Women with risk factors (low body weight, family history of osteoporotic fracture, prior fracture, smoking, long-term glucocorticoid use, malabsorption disorders, early menopause, or surgical menopause) often benefit from earlier scanning, sometimes in the early 50s or even before menopause if risk factors are significant.

The frequency of repeat DEXA scans depends on the initial result. Women with normal bone density and no significant risk factors typically rescan every 5 to 10 years. Women with osteopenia rescan every 2 to 5 years. Women on treatment for osteoporosis rescan every 1 to 2 years to assess response to therapy. The exact schedule should be individualized based on the trajectory of change over time.

What to Track and When

Beyond DEXA scans, several other markers contribute to the bone-health picture. Vitamin D level, ideally 30 to 50 ng/mL for most adults. Calcium intake from food and supplements. Magnesium status, which is involved in bone metabolism. Thyroid function, since hyperthyroidism accelerates bone loss. Cortisol if there is concern about chronic stress effects or Cushing’s-related bone loss. Sex hormone-binding globulin, since high SHBG can reduce free testosterone, which contributes to bone maintenance. Bone turnover markers (CTX, P1NP) are sometimes used to assess current rate of bone loss or response to therapy, though they are more commonly used in research than routine clinical care.

Resistance training is the lifestyle intervention with the strongest bone-density evidence. Weight-bearing exercise produces mechanical loading that signals bones to maintain density. Walking, jogging, dancing, and especially strength training all contribute. Yoga and pilates produce some bone benefit but are less effective than progressive resistance training for women specifically focused on bone density.

Combining HRT With Other Bone Strategies

For women on HRT primarily for symptom relief who also have osteopenia or early osteoporosis, the bone protection comes as a built-in second benefit. For women with more severe osteoporosis, HRT alone may not be sufficient, and combining HRT with a bisphosphonate or another bone-targeted therapy is sometimes appropriate. The decision to combine therapies is usually made in consultation between the HRT prescriber and the clinician managing the osteoporosis, often a primary care provider, endocrinologist, or rheumatologist.

For women who stop HRT at some point, the bone-protective effect ends, and bone loss resumes. Women planning to discontinue HRT should have a clear conversation with their prescriber about whether bone-targeted therapy should be added at the time of discontinuation, particularly if their DEXA scan showed osteopenia or osteoporosis when HRT was being protective.

The Bottom Line

Bone density is one of the strongest evidence-based reasons HRT exists. Estrogen prevents the accelerated bone loss that follows menopause, modestly increases bone density when started during the optimal window, and reduces fracture risk meaningfully in postmenopausal women. For women with vasomotor symptoms and osteopenia or early osteoporosis, HRT often addresses both indications with a single intervention. For women with established osteoporosis without other HRT indications, bisphosphonates are typically more appropriate. The right choice is individualized, and the conversation should include DEXA results, vitamin D status, calcium intake, exercise patterns, fracture risk factors, and goals.

Medically Reviewed By

Dr. Ashar N., DNP, APRN, FNP-C, PMHNP-BC

Co-Founder & Medical Director at Tactus Health. Dual board-certified, with clinical focus on hormone therapy, medical weight loss, and aesthetics. Sugar Hill, GA and telehealth for Georgia patients.